Shakun Malik

2.6k total citations
35 papers, 993 citations indexed

About

Shakun Malik is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Shakun Malik has authored 35 papers receiving a total of 993 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Shakun Malik's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Cancer Genomics and Diagnostics (11 papers). Shakun Malik is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Cancer Genomics and Diagnostics (11 papers). Shakun Malik collaborates with scholars based in United States, Canada and Hong Kong. Shakun Malik's co-authors include Jeffrey S. Abrams, Margaret Mooney, Carlos Jamis‐Dow, Richard Pazdur, Brian T. Collins, Eric Anderson, Cristina Reichner, Ramaswamy Govindan, Suresh S. Ramalingam and Geoffrey R. Oxnard and has published in prestigious journals such as Journal of Clinical Oncology, Nature Reviews Drug Discovery and JNCI Journal of the National Cancer Institute.

In The Last Decade

Shakun Malik

35 papers receiving 977 citations

Peers

Countries citing papers authored by Shakun Malik

Since Specialization

Citations

This map shows the geographic impact of Shakun Malik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shakun Malik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shakun Malik more than expected).

Fields of papers citing papers by Shakun Malik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shakun Malik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shakun Malik. The network helps show where Shakun Malik may publish in the future.

Co-authorship network of co-authors of Shakun Malik

This figure shows the co-authorship network connecting the top 25 collaborators of Shakun Malik. A scholar is included among the top collaborators of Shakun Malik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shakun Malik. Shakun Malik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP) 2023 ·JCO Precision Oncology ·Riha Vaidya, Joseph M. Unger, (unknown), Katherine Minichiello, Roy S. Herbst, David R. Gandara, Joel W. Neal, Ticiana Leal, Jyoti D. Patel, Konstantin H. Dragnev, Saiama N. Waqar, Martin J. Edelman, Ellen V. Sigal, Stacey J. Adam, Shakun Malik, Charles D. Blanke, Michael LeBlanc, Karen Kelly, Jhanelle E. Gray, Mary W. Redman	1
2	Integration of Immunotherapy into Adjuvant Therapy for Resected Non-Small-Cell Lung Cancer: ALCHEMIST Chemo-Io (ACCIO) 2021 ·Immunotherapy ·Jacob Sands, Sumithra J. Mandrekar, David Kozono, Geoffrey R. Oxnard, Shauna L. Hillman, Dennis A. Wigle, Ramaswamy Govindan, Jennifer W. Carlisle, Jhanelle E. Gray, Joseph K. Salama, Luis E. Raez, Apar Kishor Ganti, Nathan R. Foster, Shakun Malik, Jeffrey D. Bradley, Karen Kelly, Suresh S. Ramalingam, Thomas E. Stinchcombe	17
3	P1.01-12 Trends in the National Cancer Institute (NCI) Sponsored Lung Cancer Clinical Trials Pre and Post NCI’s National Clinical Trials Network (NCTN) 2019 ·Journal of Thoracic Oncology ·Shakun Malik, (unknown), Andrea Denicoff, Jian Zhao, Edward L. Korn, Margaret Mooney	1
4	Steps forward for cancer precision medicine 2017 ·Nature Reviews Drug Discovery ·Roberto Salgado, Helen M. Moore, John W.M. Martens, Tracy Lively, Shakun Malik, Ultan McDermott, Stefan Michiels, Jeffrey A. Moscow, Sabine Tejpar, Tawnya C. McKee, Denis Lacombe	23
5	Clinician Perspectives on Current Issues in Lung Cancer Drug Development 2016 ·Journal of Thoracic Oncology ·Saiama N. Waqar, Philip Bonomi, Ramaswamy Govindan, Fred R. Hirsch, Gregory J. Riely, Vassiliki A. Papadimitrakopoulou, Dickran Kazandjian, Sean Khozin, Erin Larkins, (unknown), Shakun Malik, Leora Horn, Andrea Ferris, Alice T. Shaw, Pasi A. Jänne, Tony Mok, Roy S. Herbst, Patricia Keegan, Richard Pazdur, Gideon M. Blumenthal	8
6	Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression 2016 ·JNCI Journal of the National Cancer Institute ·Eric C. Polley, Mark W. Kunkel, David M. Evans, Thomas Silvers, René Delosh, Julie Laudeman, (unknown), Russell Reinhart, Michael Selby, John Connelly, Erik Harris, Nicole Fer, Dmitriy Sonkin, Gurmeet Kaur, Anne Monks, Shakun Malik, Joel Morris, Beverly A. Teicher	106
7	Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe 2016 ·Clinical Lung Cancer ·Ameen A. Salahudeen, Manali I. Patel, Paul Baas, Walter J. Curran, Jeffrey D. Bradley, David R. Gandara, Glenwood Goss, Tony Mok, Suresh S. Ramalingam, Everett E. Vokes, Shakun Malik, Heather A. Wakelee	2
8	ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer. 2015 ·Journal of Clinical Oncology ·David E. Gerber, Geoffrey R. Oxnard, Sumithra J. Mandrekar, Suzanne E. Dahlberg, Shakun Malik, Margaret Mooney, Jeffrey S. Abrams, Pasi A. Jänne, Tianhong Li, Suresh S. Ramalingam, Everett E. Vokes, Ramaswamy Govindan	4
9	National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network 2014 ·American Society of Clinical Oncology Educational Book ·Jeffrey S. Abrams, Barbara A. Conley, Margaret Mooney, James A. Zwiebel, Alice P. Chen, John J. Welch, Naoko Takebe, Shakun Malik, Lisa M. McShane, Edward L. Korn, Mickey Williams, Louis M. Staudt, James H. Doroshow	122
10	Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of “Master Protocols” in Lung Cancer 2014 ·Journal of Thoracic Oncology ·Shakun Malik, Richard Pazdur, Jeffrey S. Abrams, Mark A. Socinski, William T. Sause, David H. Harpole, John J. Welch, Edward L. Korn, Claudio Dansky Ullmann, Fred R. Hirsch	18
11	Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer 2013 ·Journal of Thoracic Oncology ·Alberto Chiappori, Charles C. Williams, Donald W. Northfelt, John W. Adams, Shakun Malik, Martin J. Edelman, Peter J. Rosen, David A. Van Echo, Mark S. Berger, Eric B. Haura	24
12	A phase 1 study of efatutazone, an oral peroxisome proliferator‐activated receptor gamma agonist, administered to patients with advanced malignancies 2012 ·Cancer ·Michael J. Pishvaian, John L. Marshall, Andrew J. Wagner, Jimmy Hwang, Shakun Malik, Ion Cotarla, John F. Deeken, Aiwu Ruth He, (unknown), Abdel‐Baset Halim, Hamim Zahir, Catherine Copigneaux, Kejian Liu, Robert A. Beckman, George D. Demetri	60
13	A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy 2012 ·Cancer Chemotherapy and Pharmacology ·Michael J. Pishvaian, Rebecca Slack, (unknown), Jan H. Beumer, Marion L. Hartley, Ion Cotarla, John F. Deeken, Aiwu Ruth He, Jimmy J. Hwang, Shakun Malik, (unknown), Minetta C. Liu, Beth Elston, (unknown), Merrill J. Egorin, John L. Marshall	14
14	A Phase I Trial of Bexarotene in Combination With Docetaxel in Patients With Advanced Solid Tumors 2011 ·Clinical Lung Cancer ·Shakun Malik, (unknown), Michael J. Pishvaian, (unknown), John L. Marshall, Jimmy Hwang	8
15	P3-112: Initial phase 1 results of gemcitabine, carboplatin and IMO-2055, a toll like receptor 9 (TLR9) agonist, in patients (pts) with advanced solid tumors 2007 ·Journal of Thoracic Oncology ·Shakun Malik, Jimmy Hwang, Ion Cotarla, Timothy J. Sullivan, Robert W. Karr, John B. Marshall	8
16	Complications of Thoracic Computed Tomography–Guided Fiducial Placement for the Purpose of Stereotactic Body Radiation Therapy 2007 ·Clinical Lung Cancer ·(unknown), Brian T. Collins, Cristina Reichner, Eric Anderson, Carlos Jamis‐Dow, Gregory Gagnon, Shakun Malik, Blair Marshall, Thomas Chang, Filip Banovac	68
17	A Phase II Trial of ISIS 3521 in Patients with Metastatic Colorectal Cancer 2004 ·Clinical Colorectal Cancer ·John L. Marshall, (unknown), Michael D. Johnson, John Hanfelt, F. Andrew Dorr, Dorraya El‐Ashry, Michael D. Oberst, (unknown), Jon Holmlund, Shakun Malik	28
18	The Impact of Aging on Chemotherapy 2004 ·Clinical Lung Cancer ·Shakun Malik	3
19	A phase I study of HYB2055 in patients (pts) with advanced solid malignancies 2004 ·Journal of Clinical Oncology ·Jimmy J. Hwang, (unknown), A. Amin, Martin Rr, Thomas Sullivan, Timothy F. Burns, Swati Agrawal, Myron J. Waxdal, Shakun Malik, John L. Marshall	7
20	Closure of tracheoesophageal fistulas with primary chemotherapy in patients with esophageal cancer 1994 ·Cancer ·Shakun Malik, Steven H. Krasnow, Robert G. Wadleigh	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact